Blood Vessel Study
- The endothelium is the inner lining of blood vessels. The cells in this lining help regulate blood flow and immune system function. Problems with endothelial cells can contribute to heart disease, high blood pressure, and diabetes. Certain genes or parts of genes may be related to problems with endothelial function. Researchers want to study healthy adults who have genes that may affect their endothelial function. More information on these genes may provide more information on genetic risk for certain diseases.
- To study healthy adults who have genetic markers related to endothelial cell problems.
- Healthy volunteers between 18 and 65 years of age.
- Current participants of the Environmental Polymorphisms Registry and have certain genes related to endothelial cell problems.
- Participants will have a single study visit to collect information and samples.
- Participants will be screened with a physical exam and medical history. Blood and urine samples will be collected.
- Participants will have an ultrasound of the artery in the arm and will be given a short-acting medication called nitroglycerin to study blood flow and blood pressure.
Brachial Artery Ultrasound
Endothelial Cell Function
|Study Design:||Time Perspective: Prospective|
|Official Title:||The Role of the Functionally Relevant Single Nucleotide Polymorphisms CYP2J2 -50G> T (CYP2J2 7) and EPHX2 9846A> G (EPHX2 K55R) in Human Endothelial Function|
- Flow-mediated dilation (FMD; endothelium-dependent vasodilation), defined as the peak percent change in brachial artery diameter, relative to baseline, after reactive hyperemia, as measured by ultrasound
- Change in digital pulsatile pressure
- Endothelium-Independent vasodilation
- Change in brachial artery blood flow velocity
- Serum levels of inflammatory markers
- Serum and urine levels of cytochrome P450 epoxygenase pathway biomarkers
|Study Start Date:||January 2012|
This is a cross-sectional, controlled study designed to investigate the association of two single nucleotide polymorphisms (SNPs) - a cytochrome P450 (CYP) epoxygenase gene CYP2J2 SNP, CYP2J2 7, and a soluble epoxide hydrolase (sEH) gene EPHX2 SNP encoding a K55R variant with altered endothelial function in humans. Healthy adults, aged 18-65 years, who are either carriers of CYP2J2 7 or EPHX2 K55R, or who are wild type (WT) with respect to either SNP will be recruited into a total of five genotype groups. Potential participants will be identified from the Environmental Polymorphisms Registry, mailed an informational letter, contacted by phone and/or email, and pre-screened for eligibility. As participants are recruited, demographic characteristics (i.e., age, gender, and race/ethnicity) will be compared between the groups, and, if necessary, recruitment will be targeted to achieve an approximate match in demographic characteristics across the groups. Pre-screened individuals will provide verbal consent to refrain from taking certain as needed supplements/medications that could alter endothelial function and recreational drugs (such as marijuana, cocaine and amphetamines) prior to the study visit, and will be mailed an informed consent form, a urine collection cup, and pre-visit instructions. Participants will attend a single study visit that will take place at the NIEHS Clinical Research Unit. During this visit, written informed consent will be obtained, and there will be a final screening and eligibility determination including medical history review, assessment of vital signs, physical examination, carbon monoxide measurement, pregnancy test (if applicable), and electrocardiogram (ECG). In eligible participants, a lipid panel will be performed and endothelial function will be assessed non-invasively by brachial artery ultrasound (i.e., flow-mediated dilation) and digital peripheral arterial tonometry. Blood and urine (first void) samples will be collected for biomarker analyses, which will be conducted in the Zeldin laboratory at NIEHS. The primary objective of the study is to determine whether individuals who are homozygous or heterozygous for the CYP2J2 7 or EPHX2 K55R SNPs exhibit altered endothelial function compared with individuals who are WT for that SNP. As a secondary objective, the impact of these two SNPs on inflammatory and CYP epoxygenase pathway biomarkers will be examined.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01524549
|Contact: Lisa B Murphy||(919) firstname.lastname@example.org|
|Contact: Darryl C Zeldin, M.D.||(919) email@example.com|
|United States, North Carolina|
|NIEHS Clinical Research Unit (CRU)||Recruiting|
|Research Triangle Park, North Carolina, United States|
|Contact: Lisa Murphy 919-541-9839 firstname.lastname@example.org|
|Principal Investigator:||Darryl C Zeldin, M.D.||National Institute of Environmental Health Sciences (NIEHS)|